2101938-42-3N#Cc1ccc(N2C[C@H](N)C[C@H](C(F)(F)F)C2)c2cccnc12BJXYHBKEQFQVES-NWDGAFQWSA-NEnpatoran (M5049) was under investigation in clinical trials for various conditions. It was investigated for systemic lupus erythematosus and cutaneous lupus erythematosus in completed trials (NCT04647708 and NCT05162586) and in a recruiting trial (NCT05540327). Additionally, M5049 was studied for COVID-19 pneumonia in a completed trial with results (NCT04448756) and is currently being recruited for a trial involving participants with dermatomyositis and polymyositis (NCT05650567).
M5049 is a small molecule Toll-like receptor (TLR)7 and TLR8 inhibitor. The drug blocks activation of TLR7/8, thereby stopping immune cell activation, inflammation, and the progression into a cyotkine storm. The drug is currently being investigated against COVID-19.
Wird geladen…
Wird geladen…
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Wird geladen…
2101938-42-3CHEMBL4802159